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Summary. This study estimates the overall effect of two influenza vaccination programs
consecutively administered in a cluster-randomized trial in western Senegal over the course
of two influenza seasons from 2009-2011. We apply cutting-edge methodology combin-
ing social contact data with infection data to reduce bias in estimation arising from con-
tamination between clusters. Our time-varying estimates reveal a reduction in seasonal
influenza from the intervention and a nonsignificant increase in H1N1 pandemic influenza.
We estimate an additive change in overall cumulative incidence (which was 6.13% in the
control arm) of -0.68 percentage points during Year 1 of the study (95% CI: -2.53, 1.18).
When H1N1 pandemic infections were excluded from analysis, the estimated change was
-1.45 percentage points and was significant (95% CI, -2.81, -0.08). Because cross-cluster
contamination was low (0-3% of contacts for most villages), an estimator assuming no
contamination was only slightly attenuated (-0.65 percentage points). These findings are
encouraging for studies carefully designed to minimize spillover. Further work is needed
to estimate contamination – and its effect on estimation – in a variety of settings.
Keywords: additive hazards, cluster-randomized, contamination, interference, over-
all effect, social network, spillover
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1. Background
Influenza is a seasonal respiratory infection that causes a substantial global burden of
morbidity and mortality, particularly among children. One meta-analysis estimated
that in 2018 the global burden of influenza among children under 5 was 109.5 million
influenza episodes, 870,000 hospital admissions for influenza virus-associated acute lower
respiratory infection, and between 13,200 and 97,200 deaths (Wang et al., 2020).
In this paper, we use state-of-the-art methodology to estimate the overall effect of
annual influenza vaccination of children age 6 months to 10 years —relative to polio
vaccination—on the incidence of influenza in western Senegal. In one analysis of surveil-
lance data in Senegal, 60% of laboratory-confirmed influenza cases were in children under
5 years of age, and 75% were in children under 16 years. While the majority of the pop-
ulation served by the surveillance clinics were children 0-15 years of age, this suggests
that a vaccination campaign focusing on young children has the potential to prevent the
bulk of influenza case burden on health clinics in Senegal (Niang et al., 2012).
The study that produced the data analyzed in this paper was a cluster-randomized
trial of 20 villages in the Niakhar Demographic Surveillance System (DSS) zone. Villages
were assigned to vaccination of children with either inactivated trivalent influenza vaccine
or an inactivated polio vaccine as an active control. There is no national recommendation
for routine influenza vaccination in Senegal, hence off-study vaccination was expected to
be minimal. The trivalent influenza vaccine has been shown to be efficacious in reducing
influenza infection in children in other settings (Madhi et al., 2014; Zimmerman et al.,
2016); the Niakhar study was testing the effectiveness of widespread immunization of
children to reduce the community burden of influenza. The primary analysis for this trial
analyzed the total effect of the intervention (Diallo et al., 2019). The total effect is based
on comparing outcomes of treated people in treated villages to those of untreated people
in control villages and accounts for protection conferred by receipt of the vaccine as well
as from reduction in exposure resulting from vaccination of others in the community. In
this paper, we consider the overall effect of the intervention. The overall effect is based
on comparing the average outcome in treated villages to the average outcome in control
villages, so takes into account the effect of the community intervention on both treated
and untreated people (Halloran et al., 1991).
The total and overall effects are of interest scientifically because of the presence of
interference in infectious disease processes. Interference —when one person’s treatment
can affect another’s outcome—is both a boon to disease prevention and a classic infer-
ential problem in infectious disease research. The benefit: the very nature of the process
induces dependence between people’s outcomes, and treating one person may prevent
another’s infection. The drawback: observations are no longer independent, and most
mainstream causal inference tools cannot account for the induced dependence. The main
approach to dealing with interference is to use cluster-randomized trials (CRT), which
allow for dependence within cluster. The assumption of no interference that would be
made in a traditional individually-randomized controlled trial is thus weakened to partial
interference—an assumption of no interference between clusters (Sobel, 2006). Viola-
tion of the partial interference condition is referred to as contamination (Hudgens and
Halloran, 2008).
Typical methods for estimating the overall effect assume partial interference (e.g., Hal-
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loran and Struchiner (1991); Liu and Hudgens (2014)). However, for socially contagious
outcomes such as infectious diseases, partial interference will not be satisfied if members
of treated clusters come in contact with people from untreated clusters (and vice-versa).
Recent methodological developments have explored incorporation of measured contam-
ination data into estimation and testing methods to explicitly adjust for interference.
See Halloran and Hudgens (2016) and Sa¨vje et al. (2020) for reviews of recent efforts to
develop causal inference methods that account for partial interference as well as more
general forms of interference. Some of these methods incorporate detailed social network
structure (Eckles et al., 2016; Toulis and Kao, 2013; Aronow et al., 2017; Ugander et al.,
2013), but such detailed network data is not always available or easy to obtain. In this
study, the complete social network was not observed, but information was collected on
rates of contacts within and between villages. Most relevant to this data structure and
to our interest in the overall effect is a method developed by Carnegie et al. (2016). It is
well known that when contamination is present, the overall effect estimate is attenuated.
The authors developed a method to explicitly incorporate measured contamination data
into the estimation procedure and demonstrated that this adjustment removes the at-
tenuation of the overall effect estimate. We apply this method to estimate the overall
effect accounting for cross-cluster contamination and compare it to the estimate that
would be obtained assuming partial interference.
This paper continues as follows. In Section 2, we describe the data; in Section 3 we
describe the causal model and data preparation. The results of causal effect estimation
are given in Section 4, and implications and limitations are discussed in Section 5.
2. Data Collection
The data were collected in a cluster-randomized clinical trial conducted in the Niakhar
Demographic Surveillance System (DSS) zone from 2009-2011. This study, ClinicalTri-
als.gov NCT00893906, is closed, and the primary results for the first year of the trial
have been published (Diallo et al., 2019). Among thirty villages in the Niakhar DSS
zone, twenty were selected as clusters for inclusion in the trial and randomized in a 1:1
ratio to receive a blinded vaccination campaign of either inactivated trivalent influenza
vaccine (TIV) or inactivated poliovirus vaccine (IPV) as an active control. From here
on, villages that received TIV will be referred to as “treated” and those that received
IPV as “control”. The same villages were followed for two influenza seasons (2009-2010
and 2010-2011). Different formulations of trivalent influenza vaccine were given during
the two years; the second formulation included the H1N1 2009 “swine” pandemic strain
of influenza, but the first formulation did not.
Within each treatment group the goal was to vaccinate up to 5,000 children 6 months
to 10 years of age in the following approximate numbers per age-group: 1,270 children
6-35 months of age; 2,835 children 36 months to 8 years of age; and 895 children 9-
10 years of age. Vaccinees received age-specific doses. In villages assigned to receive
influenza vaccine, 3,906 (78.1% of target number for vaccination) were vaccinated with
Dose 1, while 3,843 (76.9% of the target) of those in control villages were. These numbers
comprised 66.6% and 66.2% of age-eligible children, respectively.
The primary outcome of the study was laboratory-confirmed symptomatic influenza
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infection. A combination of active and passive surveillance was used for the primary
outcome in the Niakhar DSS zone. In this geographic area, residences are organized in
compounds, clusters of dwellings typically housing an extended family. For the twenty
villages randomized in the study, field workers visited compounds on a weekly basis
to inquire about the occurrence of influenza symptoms. If the person had experienced
influenza-like illness (defined as fever or feverishness, cough, sore throat, nasal conges-
tion, and/or rhinorrhea) in the past 7 days, then the field worker consented them into
the surveillance study and documented symptoms and epidemiologic data. Cases of
influenza-like illness were reported to the study center, and nasal and throat swab spec-
imens were collected. In addition, individuals seeking medical care at any of the three
Niakhar DSS health posts at any time throughout the year were assessed by health
post medical staff or a study physician to determine if the person had influenza-like ill-
ness. These individuals were consented into the surveillance study, their symptoms were
documented, and nasal and throat swab specimens were obtained for influenza testing.
When individuals with influenza-like illness enrolled into the surveillance study, they
also responded to a survey about their travel and social contact patterns during the prior
three days. For each day, the respondent provided the number of people she contacted in
her own compound in the morning and the afternoon/evening. In addition, she indicated
yes or no to whether she had visited a list of locations: another compound (up to five
could be identified in the survey), a market, mosque or church, field, school, sports field
or public place, outside the study zone, or another location. For each location visited,
the village identification code (and compound identification number, where applicable),
the time of day visited (AM, PM, or both), and the number of persons the respondent
spoke with during the visit were recorded. For additional details, refer to the example
survey form in the Appendix.
Village of residence was recorded during quarterly censuses conducted by the Niakhar
DSS (Delaunay et al., 2002, 2013). If participants moved during the trial, their departure
date, arrival date, and village of their new residence were recorded. Those who moved a
second time had their departure date (but not residence after second move) recorded as
well. The cleaning that was performed after receiving the residence data from the DSS
is described in the Appendix.
3. Analytic Methods
3.1. Causal effect estimation
In this paper, we consider two estimators for the overall effect of influenza vaccination
relative to polio vaccination. The first estimator assumes partial interference (i.e., no
contamination), and we refer to it as the no-contamination estimator. The second explic-
itly accounts for interference generated by contacts to villages of the opposite treatment
assignment; we refer to this as the contamination-adjusted estimator.
To account for contamination, we use the method developed in Carnegie et al. (2016).
This approach uses an additive hazards model (Aalen, 1989) for the time to first event
but includes a modified treatment variable to account for contacts occurring between
clusters in a cluster-randomized trial. Typically, the treatment variable Z is a binary
indicator such that Z = 1 for participants from treated villages and Z = 0 for those from
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control villages. This is the treatment variable used to calculate the no-contamination
estimator. To account for interference between clusters, we use an alternate treatment
variable M , which is the proportion of contacts of residents of the participant’s village
that are with treated villages. It can be thought of as a village-level intensity of exposure
to the treatment conditions, and will range from 0 (if all contacts reported in a village
are with control villages) to 1 (if all of the contacts reported in a village are with
treated villages). Note that if no contamination is present, then this modified treatment
variable reduces to the binary treatment variable used to calculate the no-contamination
estimator.
The additive hazards model used to obtain the no-contamination estimator for an
individual in cluster j is
λj(t|Z) = β0(t) + βZ(t)zj ,
where zj is a binary treatment indicator for cluster j. The contamination-adjusted
estimator is obtained from the following model for individual in cluster j:
λj(t|M) = β0(t) + βM (t)mj ,
where mj is the total percentage of contacts of susceptibles in cluster j that are with
treated clusters. Note that mj is a cluster-level variable, but the model is an individual-
level model, with individuals in the same cluster taking the same value for mj .
The coefficient of interest in the additive hazards model—corresponding to the treat-
ment variable—is potentially time-varying. For this reason, we report both that coeffi-
cient (visually) and the difference in cumulative hazard of influenza due to the treatment.
Because the cumulative hazard is low, this is approximately equal to the difference in
cumulative incidence due to treatment. The time-varying coefficients are visualized by
displaying the value of their integrals,
∫ t
0 βZ(t)dt and
∫ t
0 βM (t)dt, as a function of time.
These integrals represent the cumulative hazard difference over the time interval [0,t] and
are estimated using the nonparametric approach proposed by Aalen (1989). Since the
nonparametric estimation approach (based on step functions) produces curves that are
not always differentiable, the additive treatment effect is not explicitly estimated, but
it is visualized as the slope of the curve (Aalen, 1989). Estimation is implemented with
the aalen function in the R package timereg to fit the additive hazards models (Scheike
and Zhang, 2011; R Core Team, 2017), and the R code used is provided in the Appendix.
The effects are displayed together with confidence intervals based on robust (sandwich)
standard errors which take into account the clustering; these are also provided by the
aalen function.
The estimand of interest, which we will denote β(t), is the population-averaged differ-
ence in hazard of laboratory-confirmed symptomatic influenza infection associated with
a change from 0% to 100% exposure to treatment. While βˆZ(t) is a consistent estimator
for β(t) in the absence of contamination, Carnegie et al. (2016) proved that βˆM (t) is a
consistent estimator for β(t) in the presence of measured contamination.
This additive hazards model for interference has a natural correspondence to a deter-
ministic compartmental model such as an SIR model (Susceptible-Infectious-Recovered;
see, e.g., Keeling and Rohani (2008)). This relationship results from the assumption of
the compartmental model that the transmission rate is a product of the contact rate
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and the per-contact transmission probability. We provide further details on this re-
lationship in the Appendix. This correspondence supports application of our method
to influenza, which is frequently modelled with an SIR or SEIR (Susceptible-Exposed-
Infectious-Recovered) model (Coburn et al., 2009). Since the length of the exposure
state is irrelevant to modelling disease-free survival, this method gives identical results
under SIR and SEIR assumptions (Carnegie et al., 2016).
While Cox regression is frequently used for survival analysis, the Cox proportional
hazards model does not share this natural correspondence to epidemic compartmental
models. Another advantage that the additive hazards model has over the proportional
hazards model is collapsibility, which implies that the treatment effect is the causal effect
of interest whether or not covariates are included in the model.
Analyses were performed separately for Year 1 and Year 2 of the study. Inputs to the
additive hazards model are the time to event (or censoring) for each person, infection
status, and the percentage of contacts to treated clusters. Calculation of time-to-event
for each survey year is described in detail in the Appendix. One irregularity in data
collection is noteworthy: during Year 2 of the study, household surveillance was not
performed during a strike of field workers that lasted from Jan 3, 2011 through Feb 18,
2011. This could introduce bias since the rate of reporting infections during household
visits (as opposed to health posts) was higher in treated than control villages (87.5%
and 83%, respectively). To prevent such bias, we analyzed a shorter time interval for
Year 2 by censoring observations at the start of the strike. The full Year 2 estimates are
included as a secondary analysis.
3.2. Calculation of treatment exposure estimates
The treatment exposure value for village j is the proportion of contacts that susceptible
people in village j made with people in treated clusters. For control villages, this variable
is the percentage of contacts to treated villages (the contamination estimate itself). For
treated villages, however, the treatment exposure value is one minus the percentage of
contacts to people in control villages (i.e., one minus the contamination estimate).
The contact survey defined a “contact” as a conversation occurring between two
people in the same location. The contact survey collected numbers of contacts in various
locations at two time points (AM and PM) for three consecutive days: the survey day
and the two prior days. Numbers of contacts recorded on the survey day are subject
to truncation bias because most surveys were administered in the morning and exclude
contacts occurring after the time of the survey. Contact patterns for asymptomatic
participants are included in the data since some participant’s symptoms began on the
day of or the day before the survey. We analyze only data collected from the time point
two days before the survey date because this time point includes more reports from
asymptomatic people. Additionally, a social network analysis of these data found no
difference in numbers of contacts recorded the day before the survey vs. two days prior
– so there is no evidence that the earlier time point is subject to recall bias (Potter et al.,
2019).
The survey did not elicit how many of the morning contacts were repeated in the
afternoon/evening. We analyze contacts reported in the morning as treatment exposure
rates were similar between morning and afternoon contacts (Appendix Table 4).
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Our treatment exposure estimates take into account the percentage of contacts re-
ported while the respondent was visiting treated villages (Section 3.2.1) and the per-
centage of contacts reported in the respondent’s own home (compound) that occurred
to visitors from treated villages (Section 3.2.2).
3.2.1. Percentage of contacts in treated villages
For each village, we calculated the percentage of contacts reported while respondents
from that village were located in treated villages. The denominator was the sum of
contacts reported by village residents; the numerator was the sum of those contacts
whose reported location was a treated village. Contacts reported to villages that are
not in the trial were included in the denominator and are treated the same as contacts
to control villages. The numerator included contacts reported in the respondent’s own
compound if the respondent was a resident of a treated village. For participants who
moved mid-study, the village of residence is the reported village of residence at the time
of the contact survey.
We initially calculated treatment exposure rates using reports by asymptomatic peo-
ple only, assuming that this would be more representative of behavior when uninfected
and that the symptomatic people would travel less. We compared these to the es-
timates based on reports by symptomatic people and (counterintuitively) found that
symptomatic reports included slightly higher rates of contacts to clusters of the opposite
treatment assignment (Appendix Tables 5 and 6). This is likely because cross-cluster
contact rates are fairly low overall and because less data is available for asymptomatic
reports, so the small amount of data from asymptomatic respondents includes fewer non-
zero counts. Therefore we combined data from both asymptomatic and symptomatic
people to estimate the treatment exposure variable more precisely.
3.2.2. Incorporating treatment exposure from visitors to the respondent’s compound
The above approach assumes that the location of a contact reported by the respondent
indicates the residence of the person contacted. As such it does not account for visitors
to one’s compound from a cluster of the opposite treatment assignment, so may under-
estimate cross-cluster exposure. To incorporate exposure from visitors into the estimate,
we will define some notation and first consider the estimates for people living in control
clusters. Suppose there are nj people living in cluster j, and let Di denote the number
of contacts reported by person i who lives in cluster j. Let Ti denote the number of con-
tacts person i has made in a location in a treated cluster. Let pj denote the proportion
of contacts in cluster j to people from treated clusters. We have estimated this as
pˆj =
∑nj
i=1 Ti∑nj
i=1Di
We need to update the numerator to include contacts occurring within the respondent’s
own compound to visitors from other clusters. We can use estimates reported by these
visitors, rather than by respondents in cluster j, to obtain this information. Let Vtrt,j
denote the total number of contacts reported by people in any treated cluster during their
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visits to compounds in cluster j. While these contacts contribute to the denominator
in the above estimator, they do not contribute to the numerator (because they occurred
within the respondent’s assigned cluster), but should. Therefore, when j is a control
cluster, our updated estimate incorporating this exposure is:
pˆj =
∑nj
i=1 Ti + Vtrt,j∑nj
i=1Di
=
∑nj
i=1 Ti∑nj
i=1Di
+
Vtrt,j∑nj
i=1Di
The rationale for this adjustment is explained in detail in Potter et al. (2019), and an
explanation tailored to this setting is provided in the Appendix.
An analogous update is needed for residents of treated clusters. For these respondents
we need to account for visits from members of control clusters. Letting Vctr,j denote the
total number of contacts reported by people in any control cluster during their visits to
compounds in cluster j. When j is a treated cluster, our updated estimate incorporating
this exposure is:
pˆj =
∑nj
i=1 Ti − Vctr,j∑nj
i=1Di
=
∑nj
i=1 Ti∑nj
i=1Di
− Vctr,j∑nj
i=1Di
3.3. Multiple Imputation for Missing Contact Data
The submitted contact surveys had a large number of missing fields, which, if not mod-
elled appropriately, could create bias in the estimates of cross-cluster exposure. For
locations visited outside the home two days before the survey, 24% are missing time of
day, 59% are missing the number of people contacted, and 32% do not have a village
number recorded. The survey design elicited at-home contacts differently than those
that occurred outside the home: the numbers contacted at home in the morning and
in the afternoon/evening were recorded, so village and time point were not collected as
separate variables. Furthermore, in 60% of analyzed surveys, the number contacted at
home in the morning was missing.
We used multiple imputation, expanding on the procedure used in another analysis
of this data set (Potter et al., 2019) to adjust for missing contact data. For outside-
home locations, up to four variables may be missing: the response to “Was this location
visited?”, the time of day (AM or PM) the location was visited, the number of people
contacted at that location, and the village where the location is located. The responses
to whether the location was visited were imputed based on a log binomial regression
model with location type, symptom status, and age category as predictors, stratified
on day relative to the survey day. Missing times were imputed by sampling from the
distribution of non-missing times for that location type. To impute missing numbers of
contacts for non-home locations, we fit a negative binomial distribution to the reported
contact numbers, predicting the number contacted by the location, symptom status,
time of day, and age category. For at-home contacts, we predicted number contacted
based on symptom status, time of day, day relative to survey day, age category, and
gender. Missing villages for out-of-home contacts were sampled from the observed dis-
tribution of visited villages for the respondent’s village of residence, combining data from
both survey days. As such we are assuming the data are missing at random; in other
words, the predictors in our imputation model are sufficient to explain the distribution
of unobserved values (Rubin, 1976).
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Table 1. Percentages of contacts with residents of treated clusters based on (1)
contacts reported while located in treated clusters, (2) contacts in the respondent’s
own compound to visitors from clusters of the opposite treatment assignment,
and (3) total percentages of contacts to residents of treated clusters (treatment
exposure).
Treatment Percent reported Percent Treatment
Village Assignment in treated clusters from visitors exposure
Kalome Ndofane Vaccine 100 0 100
Ngayokheme Vaccine 99 0 99
Ndokh Vaccine 99 1 99
Ngangarlame Vaccine 99 0 99
Diohine Vaccine 99 0 98
Mokane Ngouye Vaccine 99 1 98
Nghonine Vaccine 98 2 96
Logdir Vaccine 95 2 93
Darou Vaccine 96 5 90
Poudaye Vaccine 93 2 90
Ngalagne Kop Control 0 0 0
Mboyene Control 0 0 0
Poultok Diohine Control 0 0 0
Bary Ndondol Control 0 1 1
Toucar Control 1 0 1
Gadiak Control 2 0 2
Godel Control 2 0 2
Khassous Control 3 0 3
Kothioh Control 3 0 3
Meme Control 14 0 14
We created twenty imputed data sets, calculated percentages of contacts to treated
clusters for each village in each of these imputed data sets, and combined the percentages
using standard rules for combining multiply imputed data (Rubin, 1987).
4. Results
Table 1 displays the treatment exposure estimates for each village enrolled in the trial
based on the multiply imputed data. For each village, we display the percentage of
contacts reported when the respondent visited treated villages, the estimated percentages
of contacts from visitors from villages of the opposite treatment assignment, as well as
the overall percent of contacts to treated villages, which was used as a covariate in the
contamination-adjusted model. The overall percentages are generally close to zero for
control villages and close to 100 for treated villages, with a few exceptions.
Our estimated time-varying treatment effects (both unadjusted and contamination-
adjusted) are displayed in Figure 1 for Year 1 of the study. Since the graph displays
the integral of the time-varying coefficients, the slopes of the curves represent the coeffi-
cients themselves - the estimated difference in hazard rates between vaccine and control
villages at each point in time. Both models indicate that the influenza vaccination pro-
gram reduces influenza through September. Then it is estimated to be ineffective until
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Fig. 1. Estimated effects of the influenza vaccination program for Year 1 (July 2009 - May 2010)
of the study. The time-varying effects are the difference in cumulative incidence of lab-confirmed
symptomatic influenza infection between groups, measured in percentage points.
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February (since no influenza was circulating), after which the program is associated with
an increase in the hazard of influenza for a month. This latter time period coincides with
the appearance of the A (H1N1) (2009) pandemic strain of influenza (A/H1N1pdm09)
in the community, which first appeared in late January 2010. See Figure 2 for a graph
of numbers of infections by influenza type and week.
Figure 3 presents the two estimators excluding cases of A/H1N1pdm09 influenza from
the analysis. Its slope represents the instantaneous effect of the influenza vaccination
program on the hazard of infection for non-pandemic strains only.
Figure 4 presents results for the second year of the study. This is the first publication
of Year 2 estimates for this trial, as the primary analysis only analyzed Year 1 (Diallo
et al., 2019). As mentioned previously, the formulation of the vaccine provided during
this year included the A/H1N1pdm09 strain, unlike the formulation provided in Year 1.
Figure 5 shows that substantially fewer infections were detected this year. We expect
reports to be lower during the strike (Jan. 1 - Feb. 18, 2011) since household surveillance
was not conducted during that time, but frequencies prior to the strike were also much
lower than in Year 1. Figure 4 shows that after a delay of approximately two months
with little effect, the two estimators both indicate that influenza vaccination reduced
incidence in Year 2. The delay is likely due to the relative sparsity of cases in the first
weeks of the year. The start of the strike mentioned in Section 3 is shown as a vertical
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Fig. 2. Weekly observed incidence of lab-confirmed symptomatic influenza infections by type
during Year 1 (July 2009 - May 2010) of the study.
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Table 3 displays the estimated difference in cumulative hazard of lab-confirmed symp-
tomatic influenza infection due to the influenza vaccination program. These are simply
the values of the curves in Figures 1, 3, and 4 for the last day of follow-up, and the
confidence intervals correspond to those in the figures. Because the cumulative hazard
is low, the difference in cumulative hazard is approximately equal to the difference in
cumulative incidence due to treatment.
The overall incidence rates are displayed in Table 2 for comparison purposes. Since
the overall incidence in the control group was 6.13%, our estimated additive effect of
-0.68% indicates the vaccination program prevented about 11% of influenza infections.
Our two estimators and confidence intervals are similar, but the no-contamination
estimators are slightly attenuated because they assume no mixing between clusters of
opposite treatment assignments. The confidence intervals for the contamination-adjusted
estimator are slightly wider, reflecting the loss of information caused by contamination,
but again, are similar. For Year 1 both effects are not statistically significant when all
infections are included but achieve significance (barely) when A/H1N1pdm09 infections
are excluded. The Year 2 estimates are statistically significant. The Year 2 estimates
are interpreted differently as they cover different time intervals; a higher difference in
cumulative incidence is expected for the longer interval if vaccine performance stays
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Fig. 3. Estimated effects of the influenza vaccination program for Year 1 (July 2009 - May
2010) of the study, excluding H1N1 2009 pandemic influenza infections. The time-varying ef-
fects are the change in the cumulative hazard of lab-confirmed symptomatic influenza infection,
measured in percentage points.
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Fig. 4. Estimated effects of the influenza vaccination program for Year 2 (July 2010 - May 2011)
of the study. The time-varying effects are the change in the cumulative hazard of lab-confirmed
symptomatic influenza infection, measured in percentage points.
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Fig. 5. Weekly observed incidence of lab-confirmed symptomatic influenza infections by type
during Year 2 (July 2010 - May 2011) of the study.
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Table 2. Incidence of influenza by treatment group and study year.
Study Year Treated Control All
Year 1, all infections 999/18200 (5.49%) 1076/17550 (6.13%) 2075/35750 (5.8%)
Year 1, excluding A/H1N1pdm09 630/18200 (3.46%) 833/17550 (4.75%) 1463/35750 (4.09%)
Year 2, all infections 224/18547 (1.21%) 341/17815 (1.91%) 565/36362 (1.55%)
the same. While bias from the strike starting Jan 1, 2011 does not impact the Year
2 estimate censored at that date, the uncensored one could be biased. The rates of
reporting infections during health post visits (as opposed to household visits) were 12.5%
in treated villages and 17% in control villages, so the vaccine effect could be overestimated
by including a time interval with only health post visits. Because the rates are similar,
and because the strike lasted 49 days of a 320-day follow-up period, the bias is likely
low.
5. Discussion
We have applied state-of-the art statistical methodology to estimate the overall effect
of a trivalent influenza vaccine program in Niakhar, Senegal. This method incorporates
social contact data together with treatment and infection data to reduce the bias in this
estimate caused by interference between clusters. Ours is the first study we know of
applying this novel method to contact and infection data collected jointly in a clinical
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Table 3. Estimated difference in cumulative incidence of influenza (measured in percent-
age points) due to the influenza vaccination program.
Contamination-Adjusted No-Contamination
Study Year Estimate 95% C.I. Estimate 95% C.I.
Year 1, all infections -0.68 [-2.53, 1.18] -0.65 [-2.40, 1.09]
Year 1, excluding A/H1N1pdm09 -1.45 [-2.81, -0.08] -1.35 [-2.64, -0.06]
Year 2 (July - Dec 2010) -0.59 [-1.01, -0.17] -0.59 [-0.99, -0.19]
Year 2 (July 2010 - May 2011) -0.73 [-1.16, -0.31] -0.73 [-1.14, -0.32]
trial setting. We produce the first estimates of contact rates between clusters of op-
posite treatment assignments for this trial and the first, to our knowledge, in Senegal.
Our results provide insight into the extent to which the standard assumption of partial
interference is violated in a trial of this structure and of the impact of this violation on
estimates.
Our time-varying effect estimates show that in Year 1 of the study, the treatment
program – vaccination of children – reduced lab-confirmed symptomatic infection with
seasonal influenza in the community. Our estimates found the treatment program to
be associated with a small (though statistically insignificant) increase in infections with
A/H1N1pdm09 influenza. While other studies have found evidence for this relation-
ship (Cowling et al., 2010; Skowronski et al., 2010), others have found evidence that triva-
lent influenza vaccination protects against A/H1N1pdm09 infection. A meta-analysis of
17 studies, including the two just mentioned, found that the overall evidence points to a
protective effect, but the authors cautioned against drawing a solid conclusion because
most of the studies reviewed were observational (Yin et al., 2012). Two subsequent ran-
domized trials also found evidence for a protective effect (Cowling et al., 2012; Mcbride
et al., 2016).
The extent of contamination measured in our data resulted in little difference be-
tween the cumulative incidence for the estimator adjusting for contamination and the
one assuming no contamination. The latter was smaller because, as has been found
in other studies, contacts to members of clusters of the opposite assignment attenuate
the estimate of the overall effect from what it would have been with no contamina-
tion (Carnegie et al., 2016; Tiono et al., 2013; Wang et al., 2014). The model we imple-
ment explicitly adjusts for contamination, correcting this under-estimation. In addition,
the standard errors associated with this adjusted estimator were larger than those for the
no-contamination estimator because information available to estimate the effect of the
treatment program decreases as mixing increases – so these intervals accurately reflect
the decrease in information from zero mixing to the small level of mixing we observed.
As noted in Carnegie et al. (2016) the approach we have used to estimate the overall
effect fails when 50% of contacts occur to clusters of the opposite treatment assignment.
This is because our method uses the contact rates between clusters to differentiate treat-
ment status, so no information distinguishing clusters is available for our approach when
mixing is at 50%.
The level of contamination in the data was fairly small: the percent of contacts to
clusters of the opposite treatment was between 0% and 3% for most villages, although
there were some outliers, with 14% being the largest observed value. To our knowledge,
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these are the first data-based contamination estimates of this type for Senegal. Our find-
ing that this amount of contamination has a negligible impact on the effect estimate may
be encouraging for researchers who carefully define cluster selection to minimize contam-
ination, as was done in this study. The villages in this trial were separated by physical
boundaries such as bodies of water and roads, and their definition as cultural/political
entities also has an impact on social contact behavior.
Our study has several limitations. First, the extent of missing data in the contact
survey is substantial. As noted previously, for locations visited outside the home two days
before the survey, 24% are missing time of day, 59% are missing the number of people
contacted, and 32% do not have a village number recorded. We used multiple imputation
to adjust for missing data, but bias is still a risk. For example, if numbers of people
contacted in villages of the opposite assignment were higher for participants who did
not respond to this question than for those who responded (and who have similar values
for covariates included the multiple imputation model), then the true contamination
values may be higher than our predicted values. This would mean that the magnitude
of the true overall effect is larger than our estimate. If, on the other hand, we have
overestimated contamination, then the true effect may be closer to our no-contamination
estimate (closer to -0.65 than -0.68). Implementation of similar surveys in the future
may be improved by a diary-based approach, in which participants fill out a paper
diary as they go about their day (Mossong et al., 2008; Be´raud et al., 2015; Melegaro
et al., 2017; Johnstone-Robertson et al., 2011; Horby et al., 2011; Fu et al., 2012; Read
et al., 2014). In addition we would recommend consideration of procedures employed
by Kiti et al. (2014), including conducting a pilot study, providing wristwatches with
pre-programmed alarms to remind participants to fill out their diary, and by assigning
“shadow” respondents to fill out the diary for illiterate participants. Alternately and
potentially more accurate would be an approach using remote wireless sensors to detect
when two participants are located within 1.5 meters of each other - a distance at which
infection may be transmitted (Kiti et al., 2016; Stehle´ et al., 2011; Fournet and Barrat,
2014; Barclay et al., 2014; Ge´nois et al., 2015).
A second limitation of the contact survey is that contacts were reported separately for
morning and afternoon time intervals without recording the extent of overlap. Because
morning and afternoon contamination estimates were similar, either is likely a reasonable
approximation to the percent of contacts to clusters of the opposite assignment during
a full day. However, it would be preferable to record numbers of contacts throughout
the entire day in future studies. We also note that contacts recorded on the day of
the survey did not contribute to analysis since truncation bias arose from the fact that
most surveys were conducted in the morning. A diary-based approach would avoid this
problem, or if interviews are conducted, they should focus on days before the survey
day. The literacy level of the population of interest should be considered in choosing the
optimal approach to collect contact data.
Finally, the type of contacts recorded in our study emphasize transmission via large
droplets (in close proximity) rather than by aerosol droplets which have a longer range.
While many studies have investigated the importance of fomite transmission, physical
contacts, small droplets, and aerosol droplets for transmission, their relative importance
is not well understood (Weber and Stilianakis, 2008; Cowling et al., 2013; Teunis et al.,
16
2010; Wei and Li, 2016; Kutter et al., 2018). Although the contact survey had lim-
itations, it seems unlikely that the true contamination levels are higher enough than
our estimated ones to substantially impact the efficacy estimates. Therefore we believe
that our conclusion that contamination was low and had only a small impact on efficacy
estimates is valid. However, careful design of the contact survey would improve data
precision if a similar approach is applied when clusters are smaller and closer. We would
recommend such studies as future research. For example, a compound-based random-
ization scheme had been considered for this trial design instead of village-based, and
in fact, the protocol allowed for both possibilities. The level of contamination for such
a design, which would likely be higher than that for villages, could be estimated with
our social network data in order to understand its potential impact on estimation. Al-
though our method adjusts for the contamination, higher contamination decreases the
information available to detect an effect. Since our approach removes the dilution from
the effect estimate while simultaneously increasing standard errors, the lost power from
contamination is not regained via our adjustment. Rather, the estimate and standard
error estimates are both more accurate than unadjusted estimates. We expect this rela-
tionship to hold for other adjustment approaches which have been proposed but, to our
knowledge, not yet applied or tested (e.g., Reiner Jr. et al. (2016)).
We also recommend collection and estimation of cross-cluster contamination for dif-
ferent types of contacts (e.g., physical contacts, sexual contacts), for various definitions
of clusters in various settings. These estimates can be used to inform future trial designs,
choose whether the method we have applied would be better than one which does not
adjust for contamination, and ultimately improve the accuracy of vaccine effectiveness
and standard error estimates.
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Table 4. Fraction and percent of contacts reported by respondents while located in treated
villages by village of residence and time of day.
Village Treatment AM Fraction AM Percent PM Fraction PM Percent
Darou Vaccine 149/149 100 123/123 100
Kalome Ndofane Vaccine 1221/1244 98 959/959 100
Poudaye Vaccine 53/65 82 47/47 100
Mokane Ngouye Vaccine 1478/1513 98 1307/1312 100
Ngayokheme Vaccine 6414/6489 99 5638/5682 99
Ndokh Vaccine 135/137 99 101/103 98
Nghonine Vaccine 303/306 99 222/231 96
Ngangarlame Vaccine 859/953 90 533/586 91
Diohine Vaccine 1195/1377 87 1104/1230 90
Logdir Vaccine 158/185 85 53/80 66
Ngalagne Kop Control 0/1052 0 0/873 0
Bary Ndondol Control 0/545 0 0/512 0
Mboyene Control 1/634 0 1/522 0
Toucar Control 6/2870 0 0/2006 0
Godel Control 0/456 0 0/449 0
Khassous Control 0/151 0 0/96 0
Kothioh Control 3/643 0 0/440 0
Meme Control 0/78 0 0/97 0
Poultok Diohine Control 0/1717 0 0/1240 0
Gadiak Control 10/466 2 10/310 3
B. Cross-village exposure summaries
This section displays analyses that informed our calculation of cross-village exposure
rates. The cross-village exposure rate for a village is defined to be the percentage of
contacts to people in clusters of the opposite treatment assignment. The tables in this
section summarize these rates based on contacts made while the respondent was visiting
other villages and do not incorporate contacts made to visitors from other villages in
the respondent’s own home. The tables summarize rates of contacts to treated villages
by village of residence; these represent the cross-village exposure rate for control villages
and one minus the cross-village exposure rate for treated villages.
Table 4 compares fractions and percentages of contacts to treated villages between
morning and afternoon/evening time intervals. Cross-cluster exposure rates are sim-
ilar for the two time intervals, with the main differences being Poudaye and Logdir,
whose higher variability than others is likely due to the small number of overall contacts
reported in those villages.
Table 5 compares fractions and percentages of contacts reported by respondents dur-
ing visits to treated villages during the morning by village number and symptom sta-
tus. Since numbers of asymptomatic reports are low and cross-village exposure is low,
cross-village exposure is lower for asymptomatic than symptomatic participants in most
villages. Table 6 shows the analogous percentages calculated based on the imputed data
and shows higher levels of cross-cluster exposure for symptomatic than asymptomatic
people.
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Table 5. Fraction and percent of contacts reported by respondents while located
in treated villages by village of residence and symptom status.
Treatment Asymptomatic Symptomatic
Village Assignment Fraction Percent Fraction Percent
Darou Vaccine 61/61 100 88/88 100
Ndokh Vaccine 28/30 93 107/107 100
Ngayokheme Vaccine 1468/1490 99 4946/4999 99
Nghonine Vaccine 32/32 100 271/274 99
Kalome Ndofane Vaccine 352/359 98 869/885 98
Mokane Ngouye Vaccine 178/183 97 1300/1330 98
Ngangarlame Vaccine 171/174 98 688/779 88
Diohine Vaccine 555/610 91 640/767 83
Poudaye Vaccine 6/6 100 47/59 80
Logdir Vaccine 58/58 100 100/127 79
Ngalagne Kop Control 0/258 0 0/794 0
Bary Ndondol Control 0/4 0 0/541 0
Mboyene Control 0/86 0 1/548 0
Toucar Control 0/839 0 6/2031 0
Godel Control 0/316 0 0/140 0
Khassous Control 0/19 0 0/132 0
Meme Control 0/30 0 0/48 0
Poultok Diohine Control 0/559 0 0/1158 0
Kothioh Control 0/157 0 3/486 1
Gadiak Control 0/137 0 10/329 3
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Table 6. Percent of contacts reported by respondents while located
in treated villages by village of residence and symptom status based on
multiply imputed data.
Treatment
Village Assignment All Asymptomatic Symptomatic
Kalome Ndofane Vaccine 100 100 100
Ngangarlame Vaccine 99 100 99
Diohine Vaccine 99 100 98
Mokane Ngouye Vaccine 99 100 99
Ngayokheme Vaccine 99 99 99
Ndokh Vaccine 99 99 99
Nghonine Vaccine 98 99 98
Logdir Vaccine 95 94 96
Darou Vaccine 96 90 100
Poudaye Vaccine 93 84 95
Ngalagne Kop Control 0 0 0
Bary Ndondol Control 0 0 0
Mboyene Control 0 0 0
Poultok Diohine Control 0 1 0
Toucar Control 1 1 0
Gadiak Control 2 3 2
Godel Control 2 1 3
Khassous Control 3 0 3
Kothioh Control 3 2 4
Meme Control 14 0 20
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C. Calculation of time-to-event
We restrict our analysis to the twenty villages enrolled in the cluster-randomized trial as
these villages received both active and passive surveillance while the other ten received
only passive surveillance. The surveillance period for Year 1 was July 15, 2009 to May
31, 2010. These dates determined the start and end of follow-up participants with the
following exceptions:
• Start of follow-up was the date participants moved to the study area if the move
took place after surveillance began.
• If participants moved out of the study area or to a cluster of the opposite treatment
assignment during surveillance, their end of follow-up was the move date.
Time-to-infection was calculated by subtracting the start of follow-up from the sample
collection date for infected people; censoring times were calculated based on start and
end of follow-up for uninfected people.
Thirteen participants were excluded from analysis because of inconsistencies in their
recorded residence data. In addition, those who moved to the study area after the
end of Year 1, and those who were infected before moving to the study area or before
follow-up began were excluded. Because the primary analysis did not censor or exclude
participants based on their residence data, our counts of participants and cases differ
slightly from that paper (Diallo et al., 2019).
Time to event for Year 2 (for which surveillance covered July 15, 2010 to May 31,
2011) was calculated analogously. However, during Year 2 of the study, household-based
surveillance did not occur from January 1, 2011 to February 18, 2011 due to a strike
of employees performing this surveillance, so only infections reported in health posts
were recorded during that time period. This could cause bias if the proportions of
infections observed at home compared to in health posts different between treatment
arms. During the non-strike period of Year 2, proportions of lab-confirmed symptomatic
influenza infections reported during household visits were 83.07% in the control group
and 87.50% in the vaccine group, respectively (Table 7). Since infections for control arm
participants were reported more frequently in health posts than those for vaccine arm
participants, the differential reporting could create bias in the efficacy estimate, making
the vaccine appear more effective than it actually is. Inverse probability weighting was
considered to correct this bias (Seaman and White, 2013). Such an approach would entail
up-weighting the observed infections during the strike by 10.1693 = 5.91 in the control
arm and 10.1250 = 8.00 in the vaccine arm, and down-weighting the people classified as
uninfected throughout the study period (since some of these would have had infections
that would have been detected during household surveillance during the strike). This
approach would assume that health post visiting behavior was the same during the
strike and outside of the strike. However, the data indicate that that assumption does
not hold. Outside of the strike, 66% of infections reported in health posts were in the
control group, but during the strike, 78% were. The larger proportion of up-weighted
control group infections resulted in a weighted overall effect estimate that was higher,
rather than lower, than the unweighted one. As the assumption required by inverse
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Table 7. Reporting rates of lab-confirmed symptomatic
infection by location within each treatment arm during
Year 2, excluding the strike period
Control Vaccine
Percent reported in compounds 83.07 87.50
Percent reported in health posts 16.93 12.50
probability weighting did not hold, we instead censored the Year 2 data at the last day
before the strike. A secondary analysis includes all of the Year 2 data.
D. Correspondence to compartmental model for infectious disease transmis-
sion
The additive hazards model applied in this paper has a natural correspondence to an
SIR (Susceptible-Infected-Removed) compartmental model for disease transmission. To
see this, recall that the contamination-adjusted estimator for an individual in cluster j
is obtained from the following additive hazards model:
λj(t|M) = β0(t) + βM (t)mj ,
where mj is the total percentage of contacts of susceptibles in cluster j that are with
treated clusters.
Next, we define the following notation:
(a) Yk(t) = the number of infected people in cluster k at time t
(b) κ = the overall average contact rate
(c) ηk = the per-contact transmission probability of infectives in cluster k
(d) mjk = the percentage of contacts from people in cluster j with those in cluster k
(e) αjk = the rate of new infections among susceptibles in cluster j from infectives in
cluster k
(f) Nk = the population size of cluster k. For simplicity, we assume a fixed population
size in each cluster.
The SIR compartmental model assumes that the rate of transmission from infectives
in cluster k to susceptibles in cluster j is the product of the overall contact rate, the
percentage of contacts from cluster j that are to people in cluster k, and the per-contact
transmission probability: αjk = κmjkηk. The hazard function of a susceptible in cluster
j is found by summing these cluster-specific transmission rates, weighted by their cluster-
specific proportions of infectives, across all clusters:
λj(t) =
c∑
k=1
αjk
Yk(t)
Nk
(1)
To simplify notation, we define νj(t) = κηj
Yj(t)
Nj
, so
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λj(t) =
c∑
k=1
αjk
Yk(t)
Nk
=
c∑
k=1
mjkνk(t) (2)
The estimand of interest, which we will denote β(t), is the population-averaged dif-
ference in hazard of infection associated with a change from 0% to 100% exposure to
treatment. That is, β(t) = ν¯trt(t)− ν¯ctr(t), where ν¯trt(t) is the average of ν(t) in treated
clusters and ν¯ctr(t) is the average of ν(t) in control clusters. While βˆZ(t) is a consistent
estimator for β(t) in the absence of contamination, Carnegie, Rui, and Wang proved
that βˆM (t) is a consistent estimator for β(t) in the presence of measured contamina-
tion. (Carnegie et al., 2016)
If we assume that the individual hazards of infection are identical within a cluster,
then the instantaneous rate of change of the number of infected individuals in cluster
i at time t is found by summing the individual hazards of all susceptibles in cluster i.
Letting Si(t) denote the number of susceptibles in cluster i at time t and substituting
from (2) yields:
dYi(t)
dt
= Si
c∑
j=1
αij
Yj(t)
Nj
=
c∑
j=1
αij
Yj(t)Si(t)
Nj
,
which corresponds to an SIR model with no birth and or death. A similar expression
for the rate of change of susceptibles is analogously derived, and generalizations such
as birth, death, and the addition of an exposed state for an SEIR model are addressed
in Carnegie et al. (2016).
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E. Rationale for adjustment in estimated contamination estimates based on re-
ports from visitors to the respondent’s compound
We define the following notation as described in the main text:
• nj = number of people living in cluster j
• Di = number of contacts reported by person i
• Ti = number of contacts person i made in a location in a treated cluster.
• pj = the proportion of contacts from cluster j to treated clusters.
• Vtrt,j = the total number of contacts reported by people in any treated cluster
during their visits to compounds in cluster j.
We initially estimated pj with
pˆj =
∑nj
i=1 Ti∑nj
i=1Di
The numerator does not include contacts occurring within the respondent’s own com-
pound to visitors from other clusters, since these occurred within the respondent’s as-
signed cluster. We can use estimates reported by visitors from clusters of the opposite
assignment, rather than by respondents in cluster j, to obtain this information. When
j is a control cluster, our estimator is appropriately updated by adding the percent of
contacts from treated clusters to compounds in cluster j to the contamination estimate:
pˆj =
∑nj
i=1 Ti + Vtrt,j∑nj
i=1Di
=
∑nj
i=1 Ti∑nj
i=1Di
+
Vtrt,j∑nj
i=1Di
To understand this, we will walk the reader through a toy example of a network depicted
in Figure 6, a diagram similar to that in (Potter et al., 2019).
Here, A is a control village and B is a treated village, and the red arrow indicates that
Oumar contacted Amadou while visiting Amadou’s home in village A. For simplicity,
assume all network members are surveyed. The true cross-cluster exposure value for A
is 1/7 (noting that each within-village contact is reported twice); it is 1/3 for B. Also
for simplicity, our example omits contacts occurring in non-home locations (e.g. market,
mosque, etc.), as the proposed adjustment to our estimator does not change how these
contribute to the estimates.
The depicted network is not completely observed since respondents did not report
the identity of their contacts. We will define adjacency matrices to illustrate how the
completely observed network relates to the recorded data. Define S to be an adjacency
matrix indicating contacts to members of one’s own village, so Sij = 1 if i and j made
contact and belong to the same village. S is symmetric, since if i contacted j, then j
contacted i as well. Let V denote contacts reported while a member of one cluster was
visiting a member of a cluster in the opposite treatment arm in the latter’s compound.
V is asymmetric to distinguish the host from the visitor and to align with the way these
contacts were reported, and V3,6 = 1 since person 6 visited person 3 in the home of
person 3. The recorded counts of contacts occurring in the respondent’s own compound
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Fig. 6. Toy example of a social network with corresponding adjacency matrices.
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are the row sums of H ≡ S + V . The recorded counts of contacts while the respondent
was visiting compounds in villages of the opposite treatment assignment are the column
sums of V . Our preliminary approach to estimating interference (without the proposed
adjustment) would calculate as follows:
• For village A, the denominator (total number of contacts) is the sum of the row
sums of rows 1, 2, 3 of H (total number of contacts reported in the respondent’s
home) plus the column sums of columns 1, 2, and 3 of V (total number of contacts
while the respondent visited a home in a cluster of the opposite assignment), so
the denominator is 7. The numerator is the sum of column sums of columns 1, 2,
3 of V , so the numerator is zero. Our cross-cluster exposure estimate is 0/7.
• An analogous approach for village B yields a cross-cluster exposure estimate of 1/3.
Our cross-cluster exposure estimate for A is incorrect since it does not account for the
contamination while Oumar was visiting Amadou since it occurred in Amadou’s home.
Our proposed adjustment is to subtract from the numerator of A contacts reported
by members of B and occurring in compounds within cluster A. These comprise the
upper right quadrant of matrix V, shown in black, whose sum is 1. Thus our adjusted
estimate for cross-cluster contamination for cluster A is 1/7, the correct value. A similar
adjustment for B involves the lower left quadrant of V; whose sum is zero, so the estimate
for B (which was already accurate) remains the same.
We have demonstrated the reasoning for our update to the estimator assuming that
all network members were surveyed. When network members are randomly sampled,
the rows of S and columns of V are sampled randomly, and the estimator is unbiased.
Our sampling process favored symptomatic people, who could be less likely to travel,
but the data show no evidence for difference in travel patterns based on symptom status,
as evidenced by Figure 7. This figure displays the location distribution of contacts by
symptom status and time of day based on the multiply imputed data set. Standard
errors were calculated by generating 500 nonparametric bootstrap resamples of each
imputed data set, pooling across the imputed data sets, and then calculating the 2.5%
and 97.5% quantiles for each location proportion (Schomaker and Heumann, 2018).
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Fig. 7. Location distribution of contacts by symptom status and time interval. Note: This figure
has been published in (Potter et al., 2019) and is reproduced with permission of the authors.
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F. R code
library(dplyr)
library(knitr)
library(xtable)
library(survival)
library(timereg)
# Function to compute change in cumulative hazard
# due to treatment over some number of years
cumulInc <- function(Y, inf.time, years, cens){
Xt = solve(t(Y)%*%Y, t(Y))
if(length(unique(time)) < length(time)) time[cens==0] <- time[cens==0] +
runif(length(time[cens==0]),0,1)
Xt = Xt[,inf.time<(years*365) & cens == 0]
At = matrix(apply(Xt, 1, sum), nrow = 1)
vcovmat = matrix(0, ncol = dim(Xt)[1], nrow = dim(Xt)[1])
for(v in 1:dim(Xt)[2]){
if(sum(is.na(Xt[,v]))==0)
vcovmat = vcovmat + Xt[,v]%*%t(Xt[,v])
}
return(list(coefs = At, vcovmat = vcovmat))
}
#Function to update model formula with covariate terms
#including const() wrapper for time-invariance
update_form_const <- function(X, formula){
if(is.null(dim(X))){
return(update.formula(formula, .~. + const(X)))
}else{
if(is.null(names(X))){
dimnames(X)[[2]] = paste0("X", 1:dim(X)[2])
X = data.frame(X)
}
formTerms = terms(formula)
modelTerms <- c(attr(formTerms, "term.labels"), paste0("const(", names(X), ")"))
return(reformulate(modelTerms, response = attr(formTerms, "variables")[[2]]))
}
}
## Function to fit additive hazards model
## returns results for randomized treatment effect
## and overall treatment effect.
fit_addHaz <- function(time, #time of event or censoring
cens, #indicator for censoring (1 = censored, 0 = event)
trt, #randomized treatment assignment
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X = NULL, #matrix of additional covariates.
# Assumed time-invariant
mix.pct, #percent of contacts to treated clusters
clust, #cluster membership
years,
#time interval for difference in cumulative hazard
max.time=NULL, # end of follow-up for analysis
plot.trt = TRUE){
require(survival)
require(timereg)
# Resolve tied event times by adding draw from a uniform(0,1) distribution
set.seed(100)
if(length(unique(time)) < length(time)) time[cens==0] <- time[cens==0] +
runif(length(time[cens==0]),0,1)
#set up survival data
surv.data = Surv(time, 1-cens)
#get randomized treatment effect estimate and SE
if(is.null(X)){
form = surv.data ~ trt + cluster(clust)
}else{
form = update_form_const(X, surv.data ~ trt + cluster(clust))
}
surv.fit = aalen(form, max.time=max.time)
#get overall treatment effect estimate and SE
Z = mix.pct
if(is.null(X)){
form = surv.data ~ Z + cluster(clust)
}else{
form = update_form_const(X, surv.data ~ Z + cluster(clust))
}
surv.fit.adj = aalen(form, max.time=max.time)
if(plot.trt){
par(mfrow = c(1,2), mgp = c(2, 0.5, 0))
plot(surv.fit$cum[,1], surv.fit$cum[,3], type = "l",
main = "No-contamination Estimator")
plot(surv.fit.adj$cum[,1], surv.fit.adj$cum[,3], type = "l",
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main = "Contamination-adjusted Estimator")
}
#get change in cumulative incidence under randomized effect
id = which(time == max(time[time <= years*365]))
id = which (surv.fit$cum[,1]==max(surv.fit$cum[,1]))[1]
cumIncTrt = surv.fit$cum[id, 3]
sd_CIT = surv.fit$robvar.cum[id, 3]
#get change in cumulative incidence under overall effect
cumIncMix = surv.fit.adj$cum[id, 3]
sd_CIM = surv.fit.adj$robvar.cum[id, 3]
return(list(rand_fit = surv.fit,
overall_fit = surv.fit.adj,
cumIncTrt = cumIncTrt, sd_CIT = sd_CIT,
cumIncMix = cumIncMix, sd_CIM = sd_CIM))
}
# To get variance of incidence difference for covariates at values other than 0
# x1 (and x2 if wanting different values for treated (x1) and control (x2) for some reason)
# should be a vector of the same length as the covariates used in the model
incDiffX <- function(inc.res, x1, x2 = NULL){
if(is.null(x2)) x2 <- x1
sigma = inc.res$vcovmat
coef1 = matrix(c(1,1,x1), nrow = 1)
coef2 = matrix(c(1,0,x2), nrow = 1)
sd_X <- sqrt(coef1%*%sigma%*%t(coef1)+coef2%*%sigma%*%t(coef2))
return(sd_X)
}
load(’tte_dat’)
load(’intdat’)
dat=left_join(tte_dat, intdat, by=’village’)
dat$censored = 1-dat$infected
mod=fit_addHaz(time=dat$tte,
35
cens=dat$censored,
trt=factor(dat$treatment),
X = NULL,
mix.pct=dat$pct,
clust=dat$village,
years=1,
plot.trt = TRUE)
load(’tte_dat_SEASONAL’)
dat=left_join(tte_dat, intdat, by=’village’)
dat$censored = 1-dat$infected
mod=fit_addHaz(time=dat$tte,
cens=dat$censored,
trt=factor(dat$treatment),
X = NULL,
mix.pct=dat$pct,
clust=dat$village,
years=1,
plot.trt = TRUE)
load(’tte_dat_YEAR2’)
dat=left_join(tte_dat, intdat, by=’village’)
dat$censored = 1-dat$infected
BEGIN = as.Date("7/15/2010", "%m/%d/%Y") # Beginning of follow-up for this year
strike.begin = as.Date("1/1/2011", "%m/%d/%Y")
max.time = strike.begin - BEGIN ## Censor analysis at beginning of strike
mod=fit_addHaz(time=dat$tte,
cens=dat$censored,
trt=factor(dat$treatment),
X = NULL,
mix.pct=dat$pct,
clust=dat$village,
incYrs=1,
max.time=max.time,
plot.trt = TRUE)
mod
# Exploratory analysis without censoring before strike
mod=fit_addHaz(time=dat$tte,
cens=dat$censored,
trt=factor(dat$treatment),
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X = NULL,
mix.pct=dat$pct,
clust=dat$village,
years=1,
max.time=
plot.trt = TRUE)
G. Data Cleaning
Village of residence was recorded during quarterly censuses of the Niakhar population
by the Niahkar Demographic Surveillance System. Delaunay et al. (2002) If participants
moved during the trial, their departure date, arrival date, and village of their new resi-
dence were recorded. Those who moved a second time had their departure date (but not
residence after second move) recorded as well. The cleaning process for inconsistencies
in the recorded movement data is described below:
(a) In 8 cases, the departure and arrival dates of the second move were earlier than
those of the first move. For these cases, the information for second and first moves
was swapped.
(b) In 46 cases, the arrival date of the second move was earlier than the arrival and
departure dates of the first move, and the departure date of the second move was
missing. For these cases, the information for second and first moves was swapped.
After the swap, the (missing) departure date for the first move was imputed to be
the arrival date of the second.
(c) In 13 cases where the departure date of the first move was missing, it was imputed
to be the arrival date of the second move.
(d) In 83 cases where the arrival date of the second move was earlier than the departure
date of the first, the departure date of the first was recoded to equal the arrival
date of the second.
(e) In 13 cases where the departure date of the first move was earlier than the arrival
date of the first move, and the arrival date of the second move was non-missing, the
departure date of the first move was recorded to be the arrival date of the second.
(f) After these updates were made, there were 13 cases that did not have arrival and
departure dates in sequential order (i.e., arrival 1 ≤ departure 1 ≤ arrival 2 ≤
departure 2); these were excluded from analysis.
(g) The movement data was recorded by storing the village, arrival date, and depar-
ture date, of the first “stay” and the second “stay”, as well as an overall “village”
variable. In over 99% of cases, the village variable matched that of the first stay.
However, there were 168 participants for whom the overall village variable differed
from that of the first stay. This is because movement data were recorded differ-
ently for this small subset of the data. For them “village” indicated the village of
residence prior to the first stay rather than the village of the first stay. As such,
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these cases had up to three distinct residence stays recorded, which differs from
the rest of the data which only had up to two distinct stays recorded. These cases
were re-coded to be consistent with the rest of the data by transferring the village
information (which actually describes the first distinct stay) to the variables for the
first stay (so that village and village.stay.1 are consistent), transferring the infor-
mation recorded for the first stay (actually the second stay) to the variables for the
second, and removing information for the second (actually third) stay, as follows:
(i) village.stay.1 was re-coded to village
(ii) arrival.date.stay.1 was re-coded to birth.date
(iii) departure.date.stay.1 was re-coded to arrival.date.stay.1
(iv) village.stay.2 was re-coded to village.stay.1
(v) arrival.date.stay.2 was re-coded to the original arrival.date.stay.1 (the updated
departure.date.stay.1)
(vi) departure.date.stay.2 was re-coded to departure.date.stay.1
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